TEVA Stock: Price, Forecast, Financials & AI Analysis

Loading...

Loading chart...

High

33.435

Open

33.260

VWAP

33.00

Vol

11.00M

Mkt Cap

37.00B

Low

32.185

Amount

346.00M

EV/EBITDA(TTM)

11.00

Total Shares

1.00B

EV

51.00B

EV/OCF(TTM)

31.00

P/S(TTM)

2.00

Teva Pharmaceutical Industries Ltd is a Israeli-based pharmaceutical company. The Company operates through three segments: North America, Europe and International Markets. Each business segment manages entire product portfolio in its region, including generics, specialty and over-the-counter (OTC) products. In addition to these three segments, The Company has other activities, primarily the sale of active pharmaceutical ingredients (API) to third parties, certain contract manufacturing services and an out-licensing platform offering a portfolio of products to other pharmaceutical companies through its affiliate Medis.

Show More

Events Timeline

(ET)

2026-01-28

09:00:00

Teva Targets FY26 Gross Margin of 54.5%-55.5%

2026-01-28

08:50:00

Targets for 2030: Operating Profit Over 30%, FCF Exceeds $3.5B

2026-01-28

08:40:00

Company Expects FY26 CapEx of $0.5B

2026-01-28

08:40:00

FY27 Operating Profit Target 30%, FCF Over $2.7B

2026-01-28

08:20:00

Company Aims to Double Biosimilar Revenue by 2027

2026-01-28

07:20:00

Teva Reports 35% Revenue Growth in 2025, FDA Approves New Indications

2026-01-28

07:20:00

Teva Sees Revenue of $16.4B-$16.8B in 2026

2026-01-28

07:10:00

Teva Reports Q4 Revenue of $4.7B, Beating Expectations

News

an image of seekingalpha

01-27seekingalpha

PinnedTeva Pharmaceuticals to Announce Q4 Earnings on January 28

an image of seekingalpha

01-29seekingalpha

Teva Pharmaceutical Shares Dip After Six-Day Rally Amid Cautious Outlook

an image of Benzinga

Teva Pharmaceutical Q4 2025 Earnings Exceed Expectations

an image of seekingalpha

01-28seekingalpha

Teva Pharmaceutical Exceeds Q4 2025 Expectations but Projects Lower 2026 Financials

an image of seekingalpha

01-28seekingalpha

Teva Pharmaceutical Exceeds Expectations, Transitioning to Growth Story

an image of NASDAQ.COM

01-28NASDAQ.COM

Teva Pharmaceuticals to Host Q4 2025 Earnings Call

11 Analyst Rating

Wall Street analysts forecast TEVA stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for TEVA is 35.71 USD with a low forecast of 29.00 USD and a high forecast of 40.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

10 Buy

1 Hold

0 Sell

Strong Buy

Current: 0.000

Low

29.00

Averages

35.71

High

40.00

Current: 0.000

Low

29.00

Averages

35.71

High

40.00

Truist

Buy

maintain

$32 -> $36

AI Analysis

2026-01-07

Reason

Truist

Price Target

$32 -> $36

AI Analysis

2026-01-07

maintain

Buy

Reason

Truist raised the firm's price target on Teva to $36 from $32 and keeps a Buy rating on the shares. The affordable medicines theme remains attractive heading into 2026, the analyst tells investors in a research note.

Jefferies

Buy

maintain

$29 -> $40

2026-01-06

Reason

Jefferies

Price Target

$29 -> $40

2026-01-06

maintain

Buy

Reason

Jefferies raised the firm's price target on Teva to $40 from $29 and keeps a Buy rating on the shares, which the analyst introduced as a top 2026 idea. The narrative should shift in 2026 and beyond with several pipeline catalysts, but key is convincing investors to ascribe a positive terminal value to reflect R&D productivity when historically none was given, says the analyst, who expects the R&D engine to "start bearing fruit in 2026."

Unlock Full Analyst Thesis， Get the complete breakdown of rating reason for TEVA

Unlock Now

Valuation Metrics

The current forward P/E ratio for Teva Pharmaceutical Industries Ltd (TEVA.N) is 11.97, compared to its 5-year average forward P/E of 4.80. For a more detailed relative valuation and DCF analysis to assess Teva Pharmaceutical Industries Ltd 's fair value, Click here.

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.

an image of dotted line Image

5Y Average PE

4.80

Current PE

11.97

Overvalued PE

6.75

Undervalued PE

2.85

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.

an image of dotted line Image

5Y Average EV/EBITDA

6.96

Current EV/EBITDA

10.09

Overvalued EV/EBITDA

7.62

Undervalued EV/EBITDA

6.29

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.

an image of dotted line Image

5Y Average PS

0.88

Current PS

2.10

Overvalued PS

1.20

Undervalued PS

0.56

Financials

AI Analysis

Annual

Quarterly

Related Community Screener

stocks currently in bullish trend

Intellectia · 39 candidates

Market Cap: >= 10.00BList Exchange: XNYS, XNAS, XASEMoving Average Relationship: PriceAboveMA200Quarter Price Change Pct: >= $50.00Monthly Average Dollar Volume: >= 2,000,000

Ticker

Name

Market Cap$

Micron Technology Inc

439.00B

Newmont Corporation

141.00B

Carvana Co

105.00B

Freeport-McMoRan Inc

89.00B

Barrick Mining Corp

87.00B

Western Digital Corp

86.00B

give me your top pick

Intellectia · 10 candidates

Market Cap: >= 10.00BMarket Cap Category: mega, largeAnalyst Consensus: Strong BuyList Exchange: XNYS, XNAS, XASEMoving Average Relationship: PriceAboveMA20, PriceAboveMA200One Month Predict Return: >= 15.0%

Ticker

Name

Market Cap$

Ross Stores Inc

60.00B

NiSource Inc

21.00B

APi Group Corp

18.00B

Meta Platforms Inc

2.00T

EMCOR Group Inc

31.00B

Penumbra Inc

14.00B

Whales Holding TEVA

Clal Financial Management Ltd

More Investment House Ltd.

Slate Path Capital LP

Lingotto Investment Management LLP

Steadfast Capital Management LP

Meitav Investment House Ltd

Trading Trends

People Also Watch

Frequently Asked Questions

What is Teva Pharmaceutical Industries Ltd (TEVA) stock price today?

The current price of TEVA is 33.07 USD — it has decreased -0.42 % in the last trading day.

What is Teva Pharmaceutical Industries Ltd (TEVA)'s business?

Teva Pharmaceutical Industries Ltd is a Israeli-based pharmaceutical company. The Company operates through three segments: North America, Europe and International Markets. Each business segment manages entire product portfolio in its region, including generics, specialty and over-the-counter (OTC) products. In addition to these three segments, The Company has other activities, primarily the sale of active pharmaceutical ingredients (API) to third parties, certain contract manufacturing services and an out-licensing platform offering a portfolio of products to other pharmaceutical companies through its affiliate Medis.

What is the price predicton of TEVA Stock?

Wall Street analysts forecast TEVA stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for TEVA is35.71 USD with a low forecast of 29.00 USD and a high forecast of 40.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

What is Teva Pharmaceutical Industries Ltd (TEVA)'s revenue for the last quarter?

Teva Pharmaceutical Industries Ltd revenue for the last quarter amounts to 5.00B USD, increased 11.40 % YoY.

What is Teva Pharmaceutical Industries Ltd (TEVA)'s earnings per share (EPS) for the last quarter?

Teva Pharmaceutical Industries Ltd. EPS for the last quarter amounts to 0.41 USD, decreased -315.79 % YoY.

How many employees does Teva Pharmaceutical Industries Ltd (TEVA). have?

Teva Pharmaceutical Industries Ltd (TEVA) has 33892 emplpoyees as of January 30 2026.

What is Teva Pharmaceutical Industries Ltd (TEVA) market cap?

Today TEVA has the market capitalization of 37.00B USD.